A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. is a phase 2 interventional study registered as NCT06349980 by Shanghai Henlius Biotech, with 117 participants planned, started 2024-08-05 and due to reach its primary completion in 2027-02-10. Interventions recorded: HLX53 (1000mg), HLX53 (2000mg), HLX10 and HLX04.